SOLIGENIX, INC. Foreign Currency Transaction Gain (Loss), before Tax
SOLIGENIX, INC. (SNGX) reported Foreign Currency Transaction Gain (Loss), before Tax of $68 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-07
- SOLIGENIX, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $68.00.
- SOLIGENIX, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$1.52K.
- SOLIGENIX, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$166.00.
- SOLIGENIX, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$2.81K, a 589.57% decline year-over-year.
- SOLIGENIX, INC. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$11.81K, a 842.55% decline from fiscal 2024.
- SOLIGENIX, INC. foreign currency transaction gain (loss), before tax for fiscal 2024 was $1.59K, a 7.28% increase from fiscal 2023.
- SOLIGENIX, INC. foreign currency transaction gain (loss), before tax for fiscal 2023 was $1.48K.
- SOLIGENIX, INC. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$30.55K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $68.00 10-Q · filed 2026-08-07 | -$1.45K 10-Q · filed 2026-08-07 | -$1.61K derived: sum of 3 quarters · filed 2026-08-07 | -$4.43K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$1.52K 10-Q · filed 2026-05-08 | -$1.68K derived: sum of 2 quarters · filed 2026-05-08 | -$4.50K derived: sum of 3 quarters · filed 2026-05-08 | -$12.54K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$166.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$2.98K derived: sum of 2 quarters · filed 2026-03-31 | -$11.03K derived: sum of 3 quarters · filed 2026-08-07 | -$11.81K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$2.81K 10-Q · filed 2025-11-07 | -$10.86K derived: sum of 2 quarters · filed 2026-08-07 | -$11.65K 10-Q · filed 2025-11-07 | -$12.31K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$8.04K 10-Q · filed 2026-08-07 | -$8.83K 10-Q · filed 2026-08-07 | -$9.50K derived: sum of 3 quarters · filed 2026-08-07 | -$8.92K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$788.00 10-Q · filed 2026-05-08 | -$1.45K derived: sum of 2 quarters · filed 2026-05-08 | -$879.00 derived: sum of 3 quarters · filed 2026-05-08 | -$406.00 derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$666.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$91.00 derived: sum of 2 quarters · filed 2026-03-31 | $382.00 derived: sum of 3 quarters · filed 2026-03-31 | $1.59K 10-K · filed 2026-03-31 |
| 2024-09-30 | $575.00 10-Q · filed 2025-11-07 | $1.05K derived: sum of 2 quarters · filed 2025-11-07 | $2.26K 10-Q · filed 2025-11-07 | $3.43K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $473.00 10-Q · filed 2025-08-14 | $1.68K 10-Q · filed 2025-08-14 | $2.85K derived: sum of 3 quarters · filed 2025-08-14 | -$191.00 derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.21K 10-Q · filed 2025-05-09 | $2.38K derived: sum of 2 quarters · filed 2025-05-09 | -$664.00 derived: sum of 3 quarters · filed 2025-05-09 | $3.06K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.17K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$1.87K derived: sum of 2 quarters · filed 2025-03-21 | $1.85K derived: sum of 3 quarters · filed 2025-03-21 | $1.48K 10-K · filed 2025-03-21 |
| 2023-09-30 | -$3.05K 10-Q · filed 2024-11-08 | $676.00 derived: sum of 2 quarters · filed 2024-11-08 | $310.00 10-Q · filed 2024-11-08 | -$4.23K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $3.72K 10-Q · filed 2024-08-09 | $3.36K 10-Q · filed 2024-08-09 | -$1.19K derived: sum of 3 quarters · filed 2024-08-09 | -$13.80K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$366.00 10-Q · filed 2024-05-10 | -$4.91K derived: sum of 2 quarters · filed 2024-05-10 | -$17.52K derived: sum of 3 quarters · filed 2024-05-10 | $77.38K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$4.54K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$17.16K derived: sum of 2 quarters · filed 2024-03-15 | $77.74K derived: sum of 3 quarters · filed 2024-03-15 | -$30.55K 10-K · filed 2024-03-15 |
| 2022-09-30 | -$12.61K 10-Q · filed 2023-11-13 | $82.29K derived: sum of 2 quarters · filed 2023-11-13 | -$26.01K 10-Q · filed 2023-11-13 | -$42.98K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $94.90K 10-Q · filed 2023-08-21 | -$13.39K 10-Q · filed 2023-08-21 | -$30.37K derived: sum of 3 quarters · filed 2023-08-21 | -$97.34K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | -$108.29K 10-Q · filed 2023-05-15 | -$125.27K derived: sum of 2 quarters · filed 2023-05-15 | -$192.24K derived: sum of 3 quarters · filed 2023-05-15 | -$174.91K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$16.98K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$83.94K derived: sum of 2 quarters · filed 2023-03-31 | -$66.61K derived: sum of 3 quarters · filed 2023-03-31 | -$39.36K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$66.97K 10-Q · filed 2022-11-10 | -$49.64K derived: sum of 2 quarters · filed 2022-11-10 | -$22.38K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $17.33K 10-Q · filed 2022-08-12 | $44.58K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $27.25K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |